IPCA to organise seminar on innovative Ayurveda treatment for migraine
Tuesday, November 18, 2008 14:45 IST Our Bureau, Mumbai
The Mumbai-based IPCA Laboratories will organise a seminar in Mumbai on November 20 on the benefits of its innovative Ayurveda treatment protocol for migraine. The seminar will analyse the products available in the market for migraine treatment and would highlight on IPCA's new Ayurvedic Treatment Protocol (AYTP) for migraine.
Even as drugs including NSAID's, 5-HT1 Agonist, Dopamine Antagonists, ?-blockers, anti-depressants, anti-convulsants and magnesium, are used for treating and preventing migraine, the cause and cure of the disease is still a mystery to the modern science, informed company officials. The products which are available in the market are also not successful in bringing long-term cure.
On the other hand, the prolonged use of pain killers triggers the Medication Overuse Headache (MOH) or other adverse effect on human body. "Under such circumstances, it was important for us to focus on prevention of migraine than curing it. This led to the formulation of AYTP," said Vaidya Balendu Prakash, director, Padaav. AYTP, a combination of modern diagnosis with Ayurvedic treatment protocol is marketed through Thane-based Padaav speciality Ayurvedic treatment centre.
Initially, the AYTP for migraine was used in clinical practice for 15 years with significant success. "In some cases, AYTP helped reduce drastically the frequency of migraine attacks. Patients were experiencing migraine at least twice a month lasting for two to three days. AYTP helped patients to reduce their dependence on pain-killers," added Vaidya.
Ipca is conducting a promotional campaign to publicise the advantages of AYTP. "Efforts are being made with leading institutes to develop the innovation for mass uses following WHO guidelines under industry\institution partnerships in league with Department of Science and Technology, Government of India," said Premchand Godha, MD, Ipca Laboratories Ltd.
AYTP comprises of aahar (diet), vihaar (lifestyle) and aushadh (herbo-mineral) formulations. To ascertain its safety, a mixture of Ayurvedic formulations was studied in rat and mice. Acute and sub-acute toxicological studies as per the OECD guidelines were also carried out at Bombay College of Pharmacy. The study showed that the formulations were safe at given doses and also at higher doses.
Migraine is the most common form of headache and it affects nearly 150 million people across the globe. It is non-communicable disorder which is highly prevalent among 18-45-years-old among urbanites.
